My research focuses on the molecular mechanisms underlying cardiovascular disease, with emphasis on atherosclerosis, endothelial dysfunction, vascular smooth muscle cell biology, inflammation, fibrosis, and vascular calcification. I have investigated how innate immune pathways—including the NLRP3 inflammasome, CARD8, IL-1β, IL-6, IL-17, and IL1RAP signaling—drive vascular inflammation and remodeling. My contributions include demonstrating how metabolic stressors such as TMAO, cholesterol crystals, and autotaxin–lysophosphatidic acid signaling, as well as infectious triggers, promote cytokine release, neutrophil extracellular trap (NET) formation, mitochondrial dysfunction, and fibrotic responses in vascular and renal cells. In parallel, I have explored the role of genetic variants in inflammasome-related genes (e.g., CARD8, NLRP3, EIF2AK2) in human atherosclerosis, inflammatory bowel disease, and myocardial infarction, linking genetic susceptibility to systemic inflammation and cardiovascular outcomes. On the therapeutic side, my work has evaluated novel purine analogues, Affibody molecules, serotonin receptor inhibitors, and RNA aptamers as innovative strategies to modulate inflammatory and thrombotic pathways. Together, these studies provide mechanistic insight into how immune, metabolic, and genetic factors converge to drive vascular pathology, and they highlight translational opportunities to target inflammation, fibrosis, and calcification in cardiovascular disease.